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EssentialsThe regulation of platelet thrombus growth by ADAMTS13 is not well characterized.Platelet thrombus formation in a flow chamber was assessed with mCherry‐tagged ADAMTS13.ADAMTS13 colocalized with VWF and platelets to the middle and top portions of the thrombus.Platelet tethering to VWF by GPIB enhanced ADAMTS13 localization to the thrombus.

1. INTRODUCTION {#rth212196-sec-0006}
===============

von Willebrand factor (VWF) is a multimeric glycoprotein that mediates platelet adhesion and aggregation at the site of blood vessel injury under. High molecular weight VWF multimers (HMWM) exhibit greater platelet‐binding activities and have been associated with an increased risk for thrombosis. Shear stress applied to VWF causes a conformational change in VWF structure from its globular to an elongated form, exposing the platelet GPIb binding site in the VWF A1 domain[1](#rth212196-bib-0001){ref-type="ref"} and resulting in platelet tethering to VWF. GPIb binding activates the GPIIbIIIa receptor complex that mediates firm attachment of platelets through interactions with the Arg‐Gly‐Asp sequence in the VWF C4 domain, resulting in platelet thrombus formation.[2](#rth212196-bib-0002){ref-type="ref"}, [3](#rth212196-bib-0003){ref-type="ref"}

von Willebrand factor activity is regulated by the protease A disintegrin‐like and metalloprotease with thrombospondin type I repeats‐13 (ADAMTS13),[4](#rth212196-bib-0004){ref-type="ref"} that cleaves HMWM to reduce the hemostatic efficacy of VWF. Exposure of VWF to shear stress or tensile stretching forces applied by captured platelets causes VWF to undergo a conformational change from a globular to an elongated form, thereby exposing cryptic ADAMTS13‐binding exosites on VWF and facilitating ADAMTS13‐mediated proteolysis.[5](#rth212196-bib-0005){ref-type="ref"}, [6](#rth212196-bib-0006){ref-type="ref"} Using an in vitro flow chamber model, we and others have previously demonstrated that ADAMTS13 can regulate platelet thrombus formation in a VWF‐dependent manner under conditions of pathological shear.[6](#rth212196-bib-0006){ref-type="ref"}, [7](#rth212196-bib-0007){ref-type="ref"}, [8](#rth212196-bib-0008){ref-type="ref"} However, the influence of platelet‐applied tensile forces on ADAMTS13 activity within the platelet thrombus is unknown. Additionally, although we observed products of VWF cleavage by ADAMTS13 within the platelet thrombus, the localization of ADAMTS13 within the platelet thrombus has not been directly observed. In these studies, we generated a recombinant murine ADAMTS13 protein fused to the mCherry fluorophore to directly visualize the localization of ADAMTS13 within the platelet thrombus. We then characterized the contribution of tensile forces mediated by platelet‐VWF tethering involving GPIb and GPIIbIIIa receptors to ADAMTS13 localization and activity within a platelet thrombus using a flow chamber model.

2. METHODS {#rth212196-sec-0007}
==========

2.1. Plasmid construction and recombinant protein production {#rth212196-sec-0008}
------------------------------------------------------------

The mCherry cDNA (Clontech, Mountainview, CA) was cloned into the full‐length murine ADAMTS13 cDNA pcDNA3.1 following a 12‐amino acid linker (GGGSGGGGSGGG). The gain‐of‐function platelet GPIb binding mutation (V1316M)[9](#rth212196-bib-0009){ref-type="ref"} and loss‐of‐function platelet GPIIbIIIa binding mutation (RGG)[2](#rth212196-bib-0002){ref-type="ref"} were introduced by mutagenesis into the full‐length murine VWF cDNA in pCIneo[10](#rth212196-bib-0010){ref-type="ref"} using the Quikchange Site‐Directed Mutagenesis Kit (Stratagene, San Diego, CA). Recombinant mADAMTS13‐mCherry and murine VWF were produced in HEK 293 T cells by calcium phosphate transfection.[11](#rth212196-bib-0011){ref-type="ref"}, [12](#rth212196-bib-0012){ref-type="ref"} VWF:Ag was measured by enzyme‐linked immunosorbent assay (ELISA) using rabbit anti‐human VWF antibodies A0082 and P0226 (Dako, Agilent, Santa Clara, CA, USA). ADAMTS13 activity was measured by cleavage of the VWF 73mer.[13](#rth212196-bib-0013){ref-type="ref"}

2.2. Flow chamber experiments and real time visualization of rADAMTS13 cherry {#rth212196-sec-0009}
-----------------------------------------------------------------------------

A flow chamber slide was coated with collagen I/III (MP Biomedicals, Solon, OH, USA) at 300 μg/mL in sodium carbonate/bicarbonate buffer at room temperature overnight, washed with phosphate‐buffered saline (PBS), blocked with 5% bovine serum albumin for 1 hour and washed again prior to the experiment. Whole blood was obtained from ADAMTS13 knockout (KO) or VWF/ADAMTS13 double knockout (DKO) mice by cardiac puncture and anticoagulated with 200 μmol/L argatroban (Enzo Life Science, Farmingdale, NY). Platelets were labeled with 3,39‐dihexyloxacarbobyanine iodide (DiOC~6~, 1 μmol/L; Invitrogen). Two U/mL of mADAMTS13‐mCherry diluted in PBS or mock transfected media diluted in PBS were added to the whole blood and were perfused into the prepared flow chamber at the indicated shear rates for 9 minutes controlled by a syringe pump (New Era Pump Systems Inc., Farmingdale, NY, USA; NE‐1600). Platelet accumulation and ADAMTS13‐cherry association was imaged using a Quorum WaveFX‐X1 spinning disk confocal system (Quorum Technologies, Inc., Guelph, ON, Canada) with a Hamamatsu Orca high resolution camera (Hamamatsu, Japan). In some experiments, whole blood was obtained from VWF/ADAMTS13 DKO mice and 2 U/mL recombinant mADAMTS13 and 2 U/mL mVWF (WT, V1316M, RGG) were added and used for the experiments.

For the direct visualization of ADAMTS13‐cherry association with accumulating platelets, rabbit anti‐mCherry antibody (BioVision, Milpitas, CA, USA) and an anti‐rabbit IgG‐Alexa568 (Molecular Probes, Eugene, OR, USA) were incubated for 30 minutes and mixed with mADAMTS13‐mCherry for 15 minutes and added to anticoagulated blood prior to the experiments. All mouse experiments were reviewed and approved by the Queen\'s University Animal Care Committee.

2.3. Immunostaining of thrombi post‐flow chamber experiments {#rth212196-sec-0010}
------------------------------------------------------------

Thrombi were fixed with Cytoperm/Cytofix (Becton Dickinson, Franklin Lakes, NJ, USA) and immunofluorescent staining was performed to further analyze the distribution of platelets, VWF and ADAMTS13. The thrombus was permeabilized with PBS/1% Triton X‐100 for 10 minutes at room temperature, blocked with serum free protein block (Dako) for 20 minutes and incubated with a rabbit anti‐mCherry antibody overnight at 4°C, followed by goat anti‐rabbit IgG‐Alexa568 for 8 hours at room temperature. Stained thrombi were fixed with Cytoperm/Cytofix for 20 minutes at room temperature, followed by incubation with phalloidin‐Alexa488 (Molecular Probes) and anti‐VWF antibody (Dako) coupled with Alexa647 (ThermoFisher Scientific, Waltham, MA) overnight at 4°C. Thrombi were mounted in Dako fluorescence mounting medium (Dako) prior to imaging. Both isotype IgG control antibodies for ADAMTS13 and VWF staining, and staining for VWF and ADAMTS13 with thrombi formed from blood collected from VWF/ADAMTS13 DKO mice were used to confirm staining experiments.

2.4. Imaging analysis {#rth212196-sec-0011}
---------------------

Image analysis was performed on fixed and permeabilized immunostained thrombi obtained at the end of the flow chamber experiments. The surface coverage and thrombus volume were measured with ImagePro 6.0.[11](#rth212196-bib-0011){ref-type="ref"} The intensity of platelet, VWF, and ADAMTS13 accumulation was measured by the Quorum WaveFX‐X1 spinning disk confocal system. To analyze the distribution of VWF and ADAMTS13, the thrombus height was divided into three layers (top, middle, and bottom) and intensity of accumulation was measured respectively. The overlap coefficient for ADAMTS13 and VWF were measured by Coloc‐2 in Fiji Is Just ImageJ (National Institute of Health, Bethesda, MD, USA).

2.5. Data presentation and statistics {#rth212196-sec-0012}
-------------------------------------

All data and statistical analysis was performed using Graphpad Prism 6.0 (Graphpad software). The results are shown as means ± SEM. Statistical significance was assessed using Student\'s *t* tests or two‐way Analysis of variance.

3. RESULTS AND DISCUSSION {#rth212196-sec-0013}
=========================

The activity of ADAMTS13‐mCherry was first measured by a functional ELISA using the VWF73mer substrate. This proved to be comparable to wild type ADAMTS13 (data not shown) and the concentration was normalized to normal pooled plasma (defined as 1 U/mL).[12](#rth212196-bib-0012){ref-type="ref"} The ability of ADAMTS13‐mCherry to cleave urea‐treated murine rVWF was confirmed by multimeric analysis (Figure [1](#rth212196-fig-0001){ref-type="fig"}A). We next evaluated the ability of ADAMTS13‐mCherry to cleave VWF in a flow chamber model. In this model, the rate of shear within the flow chamber is initially applied at a controlled rate by the syringe pump. As the platelet thrombus grows in size, it generates a partial occlusion within the chamber that increases the localized shear stress overlying the platelet thrombus, that in turn promotes the transformation of VWF from its globular to its elongated form,[14](#rth212196-bib-0014){ref-type="ref"} thereby exposing the cryptic ADAMTS13 cleavage site on thrombus‐anchored VWF. The ability of ADAMTS13‐mCherry to reduce the platelet thrombus surface area coverage and thrombus volume in a shear‐dependent manner was confirmed after a 9‐minute perfusion (Figure [1](#rth212196-fig-0001){ref-type="fig"}B,C). We also directly visualized the association of ADAMTS13‐mCherry with platelet‐VWF structures using a fluorescently tagged anti‐mCherry antibody under conditions of very high shear (7500 s^−1^) (Figure [1](#rth212196-fig-0001){ref-type="fig"}D and Figure S1). The localization of ADAMTS13 was partially associated with platelets, and resembled VWF string‐like structures. ADAMTS13 staining was not detected at 2500 s^−1^ and 500 s^−1^ (data not shown).

![Murine A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, 13 (ADAMTS13)‐mCherry reduces murine von Willebrand factor (VWF) multimer size and decreases platelet thrombus formation in a flow chamber model. (A) ADAMTS13‐mCherry reduces the high molecular weight content of VWF multimers. Recombinant mouse VWF was treated with ADAMTS13‐mCherry (0, 0.5, 2 U/mL) in the presence of 0.75 mol/L urea and the reactions were terminated by the addition of Ethylenediaminetetraacetic acid (EDTA, 10 mmol/L). The multimer profiles of these treated proteins were confirmed on the 1% sodium dodecyl sulfate agarose gel electrophoresis. ADAMTS13‐mCherry was added to whole blood from ADAMTS13 KO mice and perfused across the collagen‐coated flow chamber. Platelets were labeled with 3,3\'‐dihexyloxacarbocyanine iodide (DiOC~6~, green). Influence of ADAMTS13‐mCherry on (B) surface area coverage and (C) platelet thrombus volume after 9 min under 500 s^−1^, 2500 s^−1^, or 7500 s^−1^ shear conditions. (D) Visualization of ADAMTS13‐mCherry at the sites of platelet accumulation. Platelets were labeled with DiOC~6~ (green). The signal from ADAMTS13‐mCherry was enhanced with an anti‐cherry antibody (red). Scale bar = 25 μm . \**P* \< 0.05, \*\**P* \< 0.01](RTH2-3-254-g001){#rth212196-fig-0001}

Although previous studies have reported the elevated presence of proteolyzed VWF within the platelet thrombus in the presence of ADAMTS13,[6](#rth212196-bib-0006){ref-type="ref"} the localization of ADAMTS13 accumulation within the platelet thrombus has not been directly imaged. We performed multicolored immunostaining of thrombi generated under conditions of moderate (500 s^−1^), high (2500 s^−1^) and very high (7500 s^−1^) shear to visualize the association between VWF, platelets, and ADAMTS13 within these thrombi (Figure [2](#rth212196-fig-0002){ref-type="fig"}).

![Association between von Willebrand factor (VWF), A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, 13 (ADAMTS13), and platelets under high and very high shear stress. 2 U/mL of ADAMTS13‐mCherry was added to the whole blood obtained from ADAMTS13 KO mice and perfused into the collagen coated flow chamber at 7500 s^−1^. After 9 min of perfusion, the thrombus was fixed and immunostaining was performed. Platelet, VWF and ADAMTS13 are shown in blue, green and red pseudo‐color, respectively. Merged images are also shown and white pseudo‐color indicates the three color co‐localization. Representative images after 9 min of perfusion from seven separate experiments are shown. (A) Longitudinal view of a representative thrombus formed under 7500 s^−1^. (B) Longitudinal view of a representative thrombus formed under 2500 s^−1^. (C) Total fluorescent intensity of platelet, VWF, and ADAMTS13 under 7500 s^−1^, 2500 s^−1^, and 500 s^−1^ are shown. (D) The difference of ADAMTS13 fluorescent intensity in the top, middle, and bottom portion of thrombus under 7500 s^−1^, 2500 s^−1^, and 500 s^−1^ are shown. Each data point represents the means of 21 areas examined (three areas randomly selected in seven independent perfusions). Data was expressed in arbitrary units (AU). (E) Ratio of ADAMTS13 to VWF staining in incorporated thrombus. \**P *\<* *0.05, \*\*^\*\*^ *P *\<* *0.0001](RTH2-3-254-g002){#rth212196-fig-0002}

The staining intensity of ADAMTS13 was measured throughout the thrombus. The amount of ADAMTS13 within the thrombus increased in a shear dependent manner, with very high shear conditions (7500 s^−1^) associated with the greatest ADAMTS13 intensity (Figure [2](#rth212196-fig-0002){ref-type="fig"}C). Moreover, this increase in ADAMTS13 localization was associated with the top and middle layers of the thrombus (Figure [2](#rth212196-fig-0002){ref-type="fig"}D). ADAMTS13 binding under conventional physiological high shear (2500 s^−1^) was observed predominantly on the top layer of thrombus where shear stress increases as the thrombus grows and the lumen of the chamber becomes increasingly stenotic with the actual shear rate being much higher than 2500 s^−1^. This pattern of ADAMTS13 accumulation did not achieve statistical significance by image analysis. In contrast, at the low shear condition (500 s^−1^), ADAMTS13 staining was very low. No significant differences in VWF or platelet staining was observed between the top, middle, and bottom portions of the thrombi under these low shear conditions (data not shown). We observed that that the ratio of ADAMTS13/VWF staining was essentially the same for thrombi formed under 7500 s^−1^ and 2500 s^−1^ shear rates, but lower at 500 s^−1^, suggesting that incorporation of ADAMTS13 into the thrombus is not just dependent on the amount of VWF:Ag present, but also on the amount of localized shear (Figure [2](#rth212196-fig-0002){ref-type="fig"}E).

Platelet‐VWF complexes are the preferred substrate for ADAMTS13 cleavage in fluid phase, where the tensile forces applied by platelets under shear transforms VWF from its globular to an elongated conformation.[5](#rth212196-bib-0005){ref-type="ref"} We observed a strong association between ADAMTS13, VWF, and platelets suggesting involvement of platelet GPIb and GPIIbIIIa receptors in facilitating these interactions. We then modified the platelet‐binding ability of our recombinant murine VWF using the gain‐of‐function GPIb binding mutation (V1316M) seen in type 2B von Willebrand disease (VWD), and the loss‐of‐function GPIIbIIIa binding mutation (RGG). Whole blood was obtained from VWF/ADAMTS13 DKO mice, supplemented with 2 U/mL of wild‐type, V1316M or RGG VWF in the presence of 2 U/mL of ADAMTS13‐mCherry, and blood was perfused in a flow chamber at a shear rate of 7500 s^−1^.

Immunofluorescent staining of wild‐type recombinant VWF was mostly associated with the middle and top layers of the platelet thrombus (Figure [3](#rth212196-fig-0003){ref-type="fig"}A). The V1316M VWF GPIb binding gain‐of‐function mutation demonstrated dramatically enhanced ADAMTS13 and VWF deposition throughout, indicating that GPIb binding mediates a significant tensile force on the VWF molecule and facilitates ADAMTS13 binding to VWF. Interestingly, type 2B VWD patients demonstrate loss of HMWMs and a bleeding phenotype related in part to increased ADAMTS13‐mediated VWF proteolysis secondary to enhanced GPIb tensile forces applied to the VWF molecule.[15](#rth212196-bib-0015){ref-type="ref"}, [16](#rth212196-bib-0016){ref-type="ref"}

![Influence of Glycoprotein Ib (GPIb), and Glycoprotein IIbIIIa (GPIIbIIIa), on the association between von Willebrand factor (VWF), A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, 13 (ADAMTS13), and platelets. (A) Wild type murine recombinant (r) VWF, (B) murine V1316M rVWF, (C) murine RGG rVWF were added to whole blood from VWF/ADAMTS13 double knockout (DKO) mice and perfused into the flow chamber, respectively. Longitudinal views of a representative thrombus after 9 min of perfusion from four separate experiments are shown. Platelet, VWF, ADAMTS13, and merged images are shown. (D) The total fluorescent intensity of platelets, VWF and ADAMTS13 are shown. Data was expressed in arbitrary units (AU). Each data point represents the means of 8 areas examined (two to three areas randomly selected in three to four independent perfusions). (E) Ratio of ADAMTS13 to VWF staining in incorporated thrombus. (F) Overlap coefficient between ADAMTS13 and VWF as determined by Coloc 2 analysis. \*\**P *\<* *0.01, \*\*^\*^ *P *\<* *0.001, \*\*^\*\*^ *P *\<* *0.0001](RTH2-3-254-g003){#rth212196-fig-0003}

In contrast, the VWF RGG variant, with loss of GPIIbIIIa binding, had minimal influence on ADAMTS13 localization (Figure [3](#rth212196-fig-0003){ref-type="fig"}C). There are several potential reasons for this observation. First, the GPIIbIIIa‐binding site on VWF is located in the C‐terminal C4 domain distal to the ADAMTS13‐binding shear‐sensitive A2 domain, and thus may have a minimal impact on A2 domain unfolding. Second, the interaction between VWF and GpIIbIIIa occurs after the initial process of VWF binding to GPIb, an event that decelerates or arrests circulating platelets so that the GPIIbIIIa‐VWF interaction may not exert as much tensile force on the VWF molecule.

The ratio of ADAMTS13/VWF staining for the V1316M VWF GPIb binding gain‐of‐function mutation is much lower when compared with the RGG variant, confirming that the amount of VWF incorporated into the thrombus is not the only factor that modifies localization of ADAMTS13. In this case, the decreased ADAMTS13/VWF ratio associated with the V1316M variant may be limited to the amount of ADAMTS13 available in this system for incorporation into the thrombus (Figure [3](#rth212196-fig-0003){ref-type="fig"}E). Importantly, the overlap coefficient between ADAMTS13 and VWF staining for all conditions is 1.0, suggesting that all ADAMTS13 incorporation in these thrombi is VWF‐dependent (Figure [3](#rth212196-fig-0003){ref-type="fig"}F).

These results suggest that ADAMTS13 function within the platelet thrombus is localized predominantly to sites of pathological shear stress. Exposure of VWF to pathological shear stress results in unfolding of the molecule, and enhances platelet GPIb‐mediated platelet adhesion, that in turn applies an additional tensile force on the VWF molecule. These shear and tensile forces unfold the ADAMTS13‐cleavage site on VWF, resulting in the reduction of HMW VWF multimers and limits further platelet thrombus growth. Under conditions of high shear, ADAMTS13 activity is exquisitely regulated so as to maintain effective hemostatic thrombus formation but preventing pathologic occlusive thrombosis.
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